MiMedx Group (MDXG) Financials

$3.64 +0.03 (+0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$3.71 +0.07 (+1.92%)

As of 05:19 PM Eastern

Annual Income Statements for MiMedx Group

This table shows MiMedx Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	29	0.39	65	-30	-26	-83	-29	-30	114	84	49
Consolidated Net Income / (Loss)	29	0.39	65	-30	-26	-49	-10	-30	58	42	49
Net Income / (Loss) Continuing Operations	29	0.39	65	-30	-26	-49	-12	-20	67	42	49
Total Pre-Tax Income	24	0.55	45	-3.40	-26	-62	-12	-20	31	57	66
Total Operating Income	24	0.88	46	-3.92	-21	-45	-7.05	-15	37	59	64
Total Gross Profit	167	191	286	323	256	209	202	220	267	289	346
Total Revenue	187	222	321	359	299	248	242	268	321	349	419
Operating Revenue	187	222	321	359	299	248	242	268	321	349	419
Total Cost of Revenue	20	31	35	36	43	39	40	48	55	60	73
Operating Cost of Revenue	20	31	35	36	43	39	40	48	55	60	73
Total Operating Expenses	143	190	240	327	277	254	209	234	230	230	282
Selling, General & Admin Expense	133	173	220	259	198	181	195	209	211	225	266
Research & Development Expense	8.41	14	18	16	11	12	9.93	13	13	12	15
Amortization Expense	0.93	2.14	1.68	1.03	1.04	1.07	0.82	0.70	0.76	0.77	0.44
Other Operating Expenses / (Income)	-	0.00	0.00	51	67	59	3.79	12	5.18	-8.70	0.00
Impairment Charge	-	-	0.00	0.00	0.45	1.03	0.05	0.00	0.00	0.45	0.00
Total Other Income / (Expense), net	-0.09	-0.34	-1.14	0.53	-4.43	-16	-5.00	-5.02	-6.48	-1.57	2.38
Interest & Investment Income	-	-	-	-	-	-	-	-5.02	-6.46	-1.01	2.93
Other Income / (Expense), net	-	-0.34	-1.05	0.00	0.28	-0.00	-0.02	-0.00	-0.03	-0.57	-0.56
Income Tax Expense	-5.17	0.16	-20	27	-0.01	-12	0.25	0.21	-37	15	18
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	2.02	-10	-9.21	0.42	0.00
Basic Earnings per Share	$0.28	$0.00	$0.61	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.40	$0.29	$0.33
Weighted Average Basic Shares Outstanding	105.93M	105.93M	106.12M	105.60M	106.95M	108.26M	110.35M	112.91M	116.50M	146.98M	147.79M
Diluted Earnings per Share	$0.26	$0.00	$0.56	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.37	$0.28	$0.32
Weighted Average Diluted Shares Outstanding	113.63M	112.65M	116.11M	105.60M	106.95M	108.26M	110.35M	112.91M	145.96M	149.05M	149.72M
Weighted Average Basic & Diluted Shares Outstanding	107.81M	108.84M	106.10M	107.10M	106.60M	111.26M	112.36M	114.08M	146.96M	147.37M	148.57M

This table shows MiMedx Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	8.72	16	43	9.26	18	8.10	-9.50	7.02	9.62	17	15
Consolidated Net Income / (Loss)	1.20	8.53	53	9.26	18	8.10	7.44	7.02	9.62	17	15
Net Income / (Loss) Continuing Operations	9.25	8.84	51	9.06	18	7.88	7.44	7.02	9.62	17	15
Total Pre-Tax Income	9.18	9.43	14	11	23	11	11	8.61	13	23	22
Total Operating Income	11	11	15	13	23	11	11	8.25	12	22	21
Total Gross Profit	68	67	73	72	72	69	76	72	80	95	99
Total Revenue	81	82	87	85	87	84	93	88	99	114	118
Operating Revenue	81	82	87	85	87	84	93	88	99	114	118
Total Cost of Revenue	14	15	14	13	15	15	17	17	19	19	19
Operating Cost of Revenue	14	15	14	13	15	15	17	17	19	19	19
Total Operating Expenses	57	56	57	59	49	58	65	63	68	73	78
Selling, General & Admin Expense	52	53	54	55	55	54	61	60	64	69	73
Research & Development Expense	3.67	3.08	2.43	2.84	3.01	2.92	3.57	3.33	3.30	3.70	4.76
Amortization Expense	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.10	0.10	0.11	0.13
Total Other Income / (Expense), net	-1.66	-1.69	-1.58	-1.79	-0.23	0.26	0.20	0.36	0.64	0.66	0.72
Interest & Investment Income	-1.63	-1.68	-	-1.69	0.00	0.28	-	0.51	0.74	0.79	0.90
Other Income / (Expense), net	-0.03	-0.01	0.02	-0.10	-0.24	-0.02	-0.21	-0.15	-0.10	-0.13	-0.19
Income Tax Expense	-0.07	0.59	-37	2.35	5.60	3.54	3.81	1.59	3.39	6.10	6.61
Basic Earnings per Share	$0.00	$0.06	$0.40	$0.06	$0.12	$0.05	$0.06	$0.05	$0.07	$0.11	$0.10
Weighted Average Basic Shares Outstanding	115.87M	116.30M	116.50M	146.40M	147.33M	146.96M	146.98M	147.27M	147.76M	148.04M	147.79M
Diluted Earnings per Share	$0.01	$0.06	$0.36	$0.06	$0.12	$0.05	$0.05	$0.05	$0.06	$0.11	$0.10
Weighted Average Diluted Shares Outstanding	146.86M	149.77M	145.96M	150.03M	148.90M	148.37M	149.05M	149.68M	149.32M	149.71M	149.72M
Weighted Average Basic & Diluted Shares Outstanding	116.11M	116.38M	146.96M	147.60M	146.81M	146.95M	147.37M	147.70M	147.96M	148.10M	148.57M

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-18	4.02	-2.85	18	24	27	-8.73	-21	16	22	62
Net Cash From Operating Activities	19	24	63	36	-39	-30	-1.98	-18	27	66	74
Net Cash From Continuing Operating Activities	19	24	63	36	-39	-30	-9.87	-7.97	35	67	74
Net Income / (Loss) Continuing Operations	29	0.39	65	-30	-26	-49	-12	-20	67	42	49
Depreciation Expense	1.80	3.33	4.09	5.88	6.55	5.78	4.36	3.35	3.43	6.04	15
Non-Cash Adjustments To Reconcile Net Income	17	19	23	15	-2.80	26	16	15	20	11	24
Changes in Operating Assets and Liabilities, net	-30	-1.38	-31	44	-20	-16	-19	-7.47	-56	8.15	-14
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	7.89	-9.92	-8.16	-0.93	0.00
Net Cash From Investing Activities	-0.68	-12	-5.40	-9.22	0.50	-4.56	-3.40	-2.66	-2.16	-9.58	-6.89
Net Cash From Continuing Investing Activities	-0.68	-12	-5.40	-9.22	0.50	-4.56	-3.40	-2.66	-2.16	-9.58	-6.89
Purchase of Property, Plant & Equipment	-5.83	-6.21	-5.13	-9.42	-1.75	-4.23	-3.22	-1.51	-1.99	-1.68	-1.03
Acquisitions	0.00	-7.63	-	-0.61	-0.47	-0.33	0.00	0.00	0.00	-7.86	-3.76
Other Investing Activities, net	-0.85	-0.84	-0.27	-	-	-	-0.25	-1.15	-0.17	-0.04	-2.09
Net Cash From Financing Activities	-36	-8.15	-60	-8.93	63	62	-3.35	-0.58	-8.57	-34	-5.41
Net Cash From Continuing Financing Activities	-36	-8.15	-60	-8.93	63	62	-3.35	-0.58	-8.57	-34	-5.41
Repayment of Debt	-0.50	-	-0.03	-0.00	-8.53	-89	-	-0.04	-0.05	-82	-1.00
Repurchase of Common Equity	-40	-10	-68	-7.57	0.00	-7.47	0.00	0.00	-9.52	0.00	0.00
Issuance of Debt	-	-	0.00	0.00	73	60	-	0.00	0.00	50	0.00
Other Financing Activities, net	4.56	2.23	7.91	-1.36	-1.37	-1.92	-3.35	-0.54	1.00	-2.32	-4.41

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	7.43	13	0.84	-34	21	20	16	2.02	12	23	24
Net Cash From Operating Activities	7.78	13	10	5.98	22	20	19	5.30	14	29	25
Net Cash From Continuing Operating Activities	12	13	9.27	6.79	22	20	19	5.30	14	29	25
Net Income / (Loss) Continuing Operations	9.25	8.84	51	9.06	18	7.88	7.44	7.02	9.62	17	15
Depreciation Expense	0.69	0.65	0.61	0.75	0.58	0.58	0.56	3.20	3.17	5.29	3.22
Non-Cash Adjustments To Reconcile Net Income	4.93	5.14	5.41	6.46	-4.87	4.21	5.13	5.34	5.39	7.29	6.15
Changes in Operating Assets and Liabilities, net	-2.97	-2.10	-48	-9.56	8.11	6.16	3.44	-10	-3.62	-0.00	0.39
Net Cash From Investing Activities	-0.35	-0.65	-0.48	-6.02	-0.91	0.11	-2.77	-0.41	-0.89	-5.26	-0.34
Net Cash From Continuing Investing Activities	-0.35	-0.65	-0.48	-6.02	-0.91	0.11	-2.77	-0.41	-0.89	-5.26	-0.34
Purchase of Property, Plant & Equipment	-0.30	-0.63	-0.43	-1.14	-0.47	-0.17	5.10	-0.38	-0.18	-0.19	-0.29
Other Investing Activities, net	-0.05	-0.02	-0.05	0.12	-0.43	0.28	-0.01	-0.03	-	-	-2.05
Net Cash From Financing Activities	0.00	0.37	-8.94	-33	-0.36	0.03	-0.40	-2.88	-1.09	-0.86	-0.58
Net Cash From Continuing Financing Activities	0.00	0.37	-8.94	-33	-0.36	0.03	-0.40	-2.88	-1.09	-0.86	-0.58
Repayment of Debt	-	-	-0.05	-82	-	-0.75	0.61	0.00	-	-	-1.00
Other Financing Activities, net	0.00	0.37	0.63	-1.65	-0.36	0.78	-1.01	-2.88	-1.09	-0.86	0.42

This table presents MiMedx Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	136	117	121	123	167	202	188	171	239	264	343
Total Current Assets	96	59	49	74	123	161	149	134	164	192	277
Cash & Equivalents	28	30	27	45	69	96	87	66	82	104	166
Accounts Receivable	54	-	-	0.00	32	35	40	43	54	56	76
Inventories, net	7.46	16	9.47	16	9.10	10	11	13	21	24	25
Other Current Assets	0.22	9.52	9.02	5.82	6.06	3.37	2.81	3.34	1.75	7.84	10
Plant, Property, & Equipment, net	9.48	14	14	17	12	0.00	9.17	7.86	6.97	5.94	4.71
Total Noncurrent Assets	30	44	58	31	32	41	30	29	68	66	60
Goodwill	4.04	20	20	20	20	20	20	19	19	19	19
Intangible Assets	11	23	10	9.61	7.78	6.00	5.38	5.85	5.26	12	14
Noncurrent Deferred & Refundable Income Taxes	15	0.00	26	-	-	-	-	0.00	41	28	20
Other Noncurrent Operating Assets	0.49	0.35	2.87	1.79	3.84	15	4.88	3.55	2.34	6.71	7.27
Total Liabilities & Shareholders' Equity	136	117	121	123	167	202	188	171	239	264	343
Total Liabilities	28	69	47	73	133	111	95	97	96	71	86
Total Current Liabilities	27	61	46	72	67	59	42	44	46	46	64
Short-Term Debt	0.00	-	-	0.00	3.75	-	-	-	1.00	1.00	1.50
Accounts Payable	6.63	12	8.45	15	8.71	8.77	7.39	8.45	9.05	7.41	15
Accrued Expenses	4.64	19	16	32	32	30	9.81	11	9.36	9.01	11
Current Employee Benefit Liabilities	15	13	21	23	21	18	24	21	22	24	31
Other Current Liabilities	0.53	1.48	0.65	1.82	1.40	1.47	1.57	1.83	2.89	4.51	5.79
Total Noncurrent Liabilities	1.15	0.88	1.65	1.64	65	51	53	53	50	25	22
Long-Term Debt	-	-	-	0.00	62	48	48	49	48	18	16
Other Noncurrent Operating Liabilities	1.15	0.88	1.65	1.64	3.54	3.76	4.87	4.77	2.22	7.38	5.37
Total Equity & Noncontrolling Interests	108	48	74	50	34	-0.15	0.08	-18	143	193	257
Total Preferred & Common Equity	108	48	74	50	34	-0.15	0.08	-18	143	193	257
Total Common Equity	108	48	74	50	34	-0.15	0.08	-18	143	193	257
Common Stock	163	162	165	165	147	159	166	174	276	284	299
Retained Earnings	-38	-111	-47	-77	-102	-151	-162	-192	-134	-91	-43

This table presents MiMedx Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	169	173	168	176	189	222	230	244	270	291	319
Total Current Assets	131	136	132	141	155	139	154	172	200	221	254
Cash & Equivalents	73	73	61	69	81	48	69	89	106	119	142
Accounts Receivable	38	41	45	49	49	57	53	54	62	69	78
Inventories, net	13	14	15	17	19	24	25	24	24	25	27
Prepaid Expenses	4.09	4.68	8.82	3.68	2.95	6.10	4.03	2.91	5.35	4.86	4.25
Other Current Assets	2.57	2.58	2.31	3.11	2.31	2.80	3.10	2.15	1.97	3.03	3.08
Plant, Property, & Equipment, net	0.00	7.91	7.56	7.26	7.09	7.34	6.82	6.45	5.77	5.39	5.00
Total Noncurrent Assets	38	29	29	28	27	75	69	65	65	65	60
Goodwill	20	20	20	19	19	19	19	19	19	19	19
Intangible Assets	5.14	4.99	5.71	5.57	5.40	13	12	11	11	12	11
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	39	33	31	28	27	22
Other Noncurrent Operating Assets	13	3.88	3.21	2.89	2.59	4.75	4.41	4.02	6.35	5.98	7.66
Total Liabilities & Shareholders' Equity	169	173	168	176	189	222	230	244	270	291	319
Total Liabilities	90	100	94	97	95	66	62	63	68	74	80
Total Current Liabilities	37	46	41	44	44	42	40	42	43	50	58
Short-Term Debt	-	-	-	-	-	1.00	3.20	3.86	1.13	1.25	1.38
Accounts Payable	8.08	8.82	7.82	8.15	9.17	9.70	7.60	6.92	8.87	8.50	11
Accrued Expenses	10	11	13	13	9.44	9.20	9.28	8.40	9.45	15	13
Current Employee Benefit Liabilities	17	24	18	22	23	18	18	20	19	22	28
Other Current Liabilities	1.78	1.96	1.79	2.06	1.85	4.07	2.07	2.59	4.44	3.41	4.42
Total Noncurrent Liabilities	53	54	53	52	52	24	22	21	25	24	22
Long-Term Debt	48	48	49	49	49	18	18	18	18	17	17
Other Noncurrent Operating Liabilities	4.28	5.49	4.03	3.25	2.61	5.28	3.88	2.92	7.49	6.98	5.52
Total Equity & Noncontrolling Interests	-14	-20	-18	-13	1.33	156	168	181	203	217	239
Total Preferred & Common Equity	-14	-20	-18	-13	1.33	156	168	181	203	217	239
Total Common Equity	-14	-20	-18	-13	1.33	156	168	181	203	217	239
Common Stock	169	172	179	183	188	280	275	280	287	291	297
Retained Earnings	-183	-191	-197	-196	-187	-124	-107	-99	-84	-75	-58

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	58.43%	18.38%	44.85%	11.82%	-16.67%	-17.05%	-2.50%	10.67%	20.03%	8.52%	19.99%
EBITDA Growth	194.18%	-77.28%	728.80%	-94.25%	-503.57%	-205.79%	97.70%	-1,178.11%	479.20%	58.80%	21.56%
EBIT Growth	243.15%	-97.76%	8,188.99%	-108.69%	-432.03%	-117.47%	84.42%	-108.24%	351.78%	57.19%	8.63%
NOPAT Growth	371.87%	-97.86%	10,389.68%	-104.14%	-439.25%	-114.55%	84.47%	-108.86%	892.63%	-47.19%	8.55%
Net Income Growth	373.41%	-98.68%	16,496.67%	-146.32%	14.67%	-92.67%	79.13%	-193.60%	292.83%	-27.15%	14.52%
EPS Growth	420.00%	-100.00%	0.00%	-150.00%	14.29%	-220.83%	80.52%	-120.00%	212.12%	-24.32%	14.29%
Operating Cash Flow Growth	11.93%	26.81%	163.91%	-43.13%	-210.10%	23.21%	93.45%	-802.78%	249.64%	147.24%	11.79%
Free Cash Flow Firm Growth	-699.79%	489.52%	50.60%	-33.15%	-205.69%	-6.87%	65.41%	11.81%	302.99%	66.17%	-1.78%
Invested Capital Growth	106.78%	-49.86%	20.76%	-90.21%	582.94%	39.75%	23.83%	5.86%	95.85%	-2.00%	0.81%
Revenue Q/Q Growth	7.01%	-2.32%	14.62%	1.42%	-5.13%	-3.07%	-6.83%	9.65%	4.03%	1.77%	6.40%
EBITDA Q/Q Growth	14.14%	-72.87%	121.16%	-90.22%	27.55%	-47.84%	95.21%	46.79%	9.55%	-4.21%	21.87%
EBIT Q/Q Growth	14.57%	-96.88%	161.96%	-116.27%	16.69%	-32.87%	71.04%	40.49%	12.77%	-7.40%	18.85%
NOPAT Q/Q Growth	48.30%	-96.88%	259.75%	-105.58%	16.13%	-32.82%	71.14%	40.50%	153.79%	-52.39%	18.66%
Net Income Q/Q Growth	47.97%	-98.04%	172.53%	-172.91%	52.92%	-22.66%	64.63%	-9.54%	1,242.59%	-52.05%	18.99%
EPS Q/Q Growth	44.44%	-100.00%	180.00%	-177.78%	52.94%	-14.93%	54.55%	-10.00%	3,800.00%	-52.54%	18.52%
Operating Cash Flow Q/Q Growth	-17.28%	76.61%	10.86%	-35.07%	-167.09%	29.81%	78.02%	-15.43%	145.78%	14.78%	9.10%
Free Cash Flow Firm Q/Q Growth	-1,115.28%	193.69%	115.67%	-74.84%	-42.09%	19.18%	20.49%	37.33%	45.23%	18.85%	19.46%
Invested Capital Q/Q Growth	44.48%	-66.52%	-56.28%	0.00%	172.35%	3.08%	21.60%	17.69%	80.39%	-4.51%	-5.81%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.21%	86.05%	89.03%	89.87%	85.60%	84.16%	83.63%	81.96%	83.01%	82.78%	82.56%
EBITDA Margin	14.49%	2.78%	15.91%	0.82%	-3.96%	-14.61%	-0.35%	-3.99%	12.60%	18.44%	18.68%
Operating Margin	13.01%	0.40%	14.39%	-1.09%	-7.07%	-18.29%	-2.91%	-5.50%	11.55%	16.87%	15.26%
EBIT Margin	13.01%	0.25%	14.07%	-1.09%	-6.98%	-18.29%	-2.92%	-5.50%	11.54%	16.71%	15.13%
Profit (Net Income) Margin	15.72%	0.18%	20.16%	-8.35%	-8.55%	-19.85%	-4.25%	-11.27%	18.11%	12.16%	11.60%
Tax Burden Percent	121.29%	71.56%	143.56%	882.51%	99.98%	80.08%	85.32%	152.92%	190.08%	74.04%	73.31%
Interest Burden Percent	99.65%	100.00%	99.81%	86.57%	122.55%	135.55%	170.40%	134.05%	82.59%	98.27%	104.63%
Effective Tax Rate	-21.29%	28.44%	-43.56%	0.00%	0.00%	0.00%	0.00%	0.00%	-120.15%	26.70%	26.69%
Return on Invested Capital (ROIC)	52.07%	1.10%	156.72%	-10.80%	-83.40%	-85.56%	-10.18%	-18.68%	97.32%	39.21%	43.38%
ROIC Less NNEP Spread (ROIC-NNEP)	52.32%	2.28%	165.49%	64.22%	-39.02%	-17.61%	2.10%	51.47%	192.60%	40.47%	41.89%
Return on Net Nonoperating Assets (RNNOA)	-22.23%	-0.60%	-50.49%	-37.77%	22.53%	7.21%	-0.99%	-17.47%	-43.70%	-13.94%	-21.78%
Return on Equity (ROE)	29.85%	0.50%	106.23%	-48.57%	-60.87%	-78.34%	-11.18%	-36.15%	53.61%	25.26%	21.61%
Cash Return on Invested Capital (CROIC)	-17.54%	67.52%	137.92%	153.51%	-232.31%	-118.72%	-31.47%	-24.37%	32.52%	41.23%	42.58%
Operating Return on Assets (OROA)	19.88%	0.43%	37.88%	-3.22%	-14.40%	-24.59%	-3.63%	-8.20%	18.07%	23.18%	20.88%
Return on Assets (ROA)	24.02%	0.31%	54.27%	-24.56%	-17.64%	-26.70%	-5.27%	-16.81%	28.37%	16.87%	16.02%
Return on Common Equity (ROCE)	29.85%	0.50%	106.23%	-48.57%	-60.87%	-21.33%	0.00%	3.87%	30.78%	25.26%	21.61%
Return on Equity Simple (ROE_SIMPLE)	27.27%	0.81%	87.71%	-60.37%	-74.36%	0.00%	0.00%	167.87%	40.80%	21.97%	0.00%
Net Operating Profit after Tax (NOPAT)	30	0.63	66	-2.75	-15	-32	-4.94	-10	82	43	47
NOPAT Margin	15.78%	0.29%	20.66%	-0.76%	-4.95%	-12.80%	-2.04%	-3.85%	25.42%	12.37%	11.19%
Net Nonoperating Expense Percent (NNEP)	-0.25%	-1.18%	-8.76%	-75.03%	-44.38%	-67.95%	-12.29%	-70.15%	-95.28%	-1.26%	1.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-33.68%	42.60%	20.22%	17.06%
Cost of Revenue to Revenue	10.79%	13.95%	10.97%	10.13%	14.40%	15.84%	16.37%	18.04%	16.99%	17.22%	17.44%
SG&A Expenses to Revenue	71.22%	78.22%	68.54%	71.99%	66.23%	72.92%	80.51%	77.91%	65.67%	64.52%	63.59%
R&D to Revenue	4.49%	6.47%	5.57%	4.39%	3.72%	4.72%	4.10%	4.74%	3.94%	3.54%	3.61%
Operating Expenses to Revenue	76.21%	85.65%	74.64%	90.96%	92.67%	102.44%	86.54%	87.46%	71.46%	65.91%	67.30%
Earnings before Interest and Taxes (EBIT)	24	0.55	45	-3.92	-21	-45	-7.07	-15	37	58	63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	27	6.17	51	2.94	-12	-36	-0.84	-11	41	64	78
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.45	20.19	18.97	5.39	24.47	0.00	8,260.40	0.00	7.15	7.32	3.91
Price to Tangible Book Value (P/TBV)	10.96	210.66	31.98	13.33	126.66	0.00	0.00	0.00	8.65	8.72	4.50
Price to Revenue (P/Rev)	5.45	4.38	4.36	0.75	2.81	4.06	2.80	1.18	3.17	4.05	2.40
Price to Earnings (P/E)	34.67	2,487.95	21.63	0.00	0.00	0.00	0.00	0.00	17.53	33.33	20.64
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.88%	0.04%	4.62%	0.00%	0.00%	0.00%	0.00%	0.00%	5.71%	3.00%	4.85%
Enterprise Value to Invested Capital (EV/IC)	12.93	24.50	29.63	49.04	27.05	24.29	13.63	6.89	8.88	12.20	7.88
Enterprise Value to Revenue (EV/Rev)	5.28	4.24	4.27	0.62	2.80	4.24	3.02	1.46	3.07	3.81	2.04
Enterprise Value to EBITDA (EV/EBITDA)	36.46	152.45	26.86	75.70	0.00	0.00	0.00	0.00	24.38	20.66	10.93
Enterprise Value to EBIT (EV/EBIT)	40.61	1,724.73	30.39	0.00	0.00	0.00	0.00	0.00	26.63	22.80	13.49
Enterprise Value to NOPAT (EV/NOPAT)	33.49	1,485.93	20.69	0.00	0.00	0.00	0.00	0.00	12.09	30.81	18.24
Enterprise Value to Operating Cash Flow (EV/OCF)	52.61	39.41	21.81	6.22	0.00	0.00	0.00	0.00	36.89	20.08	11.55
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	24.24	23.51	5.70	0.00	0.00	0.00	0.00	36.17	29.30	18.59
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	1.91	0.52	0.52	0.65	0.34	0.10	0.07
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	1.80	0.52	0.52	0.65	0.34	0.09	0.06
Financial Leverage	-0.42	-0.26	-0.31	-0.59	-0.58	-0.41	-0.47	-0.34	-0.23	-0.34	-0.52
Leverage Ratio	1.24	1.62	1.96	1.98	3.45	2.93	2.12	2.15	1.89	1.50	1.35
Compound Leverage Factor	1.24	1.62	1.95	1.71	4.23	3.98	3.61	2.88	1.56	1.47	1.41
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	65.62%	34.29%	34.20%	39.48%	25.60%	9.49%	6.55%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	3.75%	0.00%	0.00%	0.00%	0.52%	1.13%	0.55%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	61.87%	34.29%	34.20%	39.48%	25.08%	8.36%	6.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	65.82%	65.74%	75.14%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	34.38%	-0.11%	0.06%	-14.61%	74.40%	90.51%	93.46%
Debt to EBITDA	0.00	0.00	0.00	0.00	-5.54	-1.32	-57.57	-4.55	1.21	0.31	0.23
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.29	1.33	46.60	1.62	-0.81	-1.31	-1.89
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-5.22	-1.32	-57.57	-4.55	1.19	0.28	0.21
Debt to NOPAT	0.00	0.00	0.00	0.00	-4.43	-1.50	-9.75	-4.71	0.60	0.47	0.38
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.23	1.51	7.89	1.68	-0.40	-1.95	-3.16
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-4.18	-1.50	-9.75	-4.71	0.59	0.41	0.35
Altman Z-Score	24.13	8.98	21.07	4.16	4.73	5.51	4.90	2.30	8.02	14.21	9.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	72.78%	100.04%	110.72%	42.58%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.60	0.98	1.06	1.04	1.83	2.71	3.51	3.08	3.57	4.21	4.32
Quick Ratio	3.18	0.50	0.60	0.63	1.51	2.22	3.01	2.50	2.95	3.51	3.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9.95	39	58	39	-41	-44	-15	-13	27	45	46
Operating Cash Flow to CapEx	322.76%	384.35%	1,227.84%	381.25%	-2,249.54%	-715.78%	-61.59%	-1,181.84%	1,347.51%	3,933.33%	7,163.89%
Free Cash Flow to Firm to Interest Expense	-115.75	0.00	671.20	0.00	-8.76	-2.73	-3.06	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	218.69	0.00	723.44	0.00	-8.37	-1.87	-0.40	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	150.93	0.00	664.52	0.00	-8.74	-2.14	-1.04	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.53	1.75	2.69	2.94	2.06	1.34	1.24	1.49	1.57	1.39	1.38
Accounts Receivable Turnover	4.66	0.00	0.00	0.00	0.00	7.33	6.39	6.42	6.63	6.36	6.37
Inventory Turnover	3.21	2.65	2.78	2.86	3.43	4.04	3.64	3.93	3.19	2.68	2.97
Fixed Asset Turnover	25.10	18.90	22.88	22.79	20.12	0.00	0.00	31.47	43.36	54.01	78.56
Accounts Payable Turnover	3.93	3.25	3.38	3.12	3.66	4.50	4.91	6.10	6.24	7.30	6.66
Days Sales Outstanding (DSO)	78.37	0.00	0.00	0.00	0.00	49.81	57.14	56.85	55.04	57.38	57.34
Days Inventory Outstanding (DIO)	113.76	137.63	131.30	127.66	106.29	90.32	100.17	92.81	114.26	136.19	122.85
Days Payable Outstanding (DPO)	92.99	112.34	108.12	116.96	99.86	81.09	74.38	59.83	58.46	50.00	54.83
Cash Conversion Cycle (CCC)	99.14	25.29	23.18	10.71	6.42	59.04	82.93	89.84	110.83	143.57	125.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	77	38	46	4.54	31	43	54	57	111	109	108
Invested Capital Turnover	3.30	3.86	7.58	14.12	16.85	6.68	4.99	4.85	3.83	3.17	3.88
Increase / (Decrease) in Invested Capital	40	-38	7.96	-42	26	12	10	3.14	54	-2.23	0.87
Enterprise Value (EV)	989	940	1,373	222	838	1,052	731	391	988	1,329	854
Market Capitalization	1,021	970	1,400	268	842	1,008	677	316	1,021	1,414	1,003
Book Value per Share	$0.99	$0.44	$0.66	$0.45	$0.31	$0.00	$0.00	($0.16)	$1.23	$1.31	$1.73
Tangible Book Value per Share	$0.86	$0.04	$0.39	$0.18	$0.06	($0.24)	($0.23)	($0.38)	$1.01	$1.10	$1.51
Total Capital	108	48	74	50	100	139	141	123	192	213	275
Total Debt	0.00	0.00	0.00	0.00	66	48	48	49	49	20	18
Total Long-Term Debt	0.00	0.00	0.00	0.00	62	48	48	49	48	18	16
Net Debt	-31	-30	-27	-45	-3.41	-48	-39	-17	-33	-84	-148
Capital Expenditures (CapEx)	5.83	6.21	5.13	9.39	1.75	4.23	3.22	1.51	1.99	1.68	1.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	38	-32	-25	-43	-9.40	5.64	19	25	37	44	49
Debt-free Net Working Capital (DFNWC)	70	-1.32	2.94	2.50	60	101	106	91	119	149	215
Net Working Capital (NWC)	70	-1.32	2.94	2.50	56	101	106	91	118	146	213
Net Nonoperating Expense (NNE)	0.10	0.24	1.63	27	11	18	5.35	20	23	0.73	-1.74
Net Nonoperating Obligations (NNO)	-31	-9.71	-27	-45	-3.41	-48	-39	-18	-32	-84	-148
Total Depreciation and Amortization (D&A)	2.77	5.62	5.93	6.86	9.02	9.13	6.24	4.05	3.43	6.04	15
Debt-free, Cash-free Net Working Capital to Revenue	20.31%	-14.27%	-7.64%	-11.87%	-3.14%	2.27%	7.88%	9.22%	11.59%	12.70%	11.61%
Debt-free Net Working Capital to Revenue	37.12%	-0.59%	0.91%	0.70%	19.94%	40.87%	43.87%	33.84%	37.10%	42.63%	51.29%
Net Working Capital to Revenue	37.12%	-0.59%	0.91%	0.70%	18.69%	40.87%	43.87%	33.84%	36.78%	41.93%	50.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.28	$0.11	$0.61	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.40	$0.29	$0.33
Adjusted Weighted Average Basic Shares Outstanding	105.93M	105.93M	106.12M	105.60M	106.95M	108.26M	110.35M	112.91M	116.50M	146.98M	147.79M
Adjusted Diluted Earnings per Share	$0.26	$0.11	$0.56	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.37	$0.28	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	113.63M	112.44M	116.11M	105.60M	106.95M	108.26M	110.35M	112.91M	145.96M	149.05M	149.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.24)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	107.81M	108.84M	106.10M	107.10M	106.60M	111.26M	112.36M	114.08M	146.96M	147.37M	148.57M
Normalized Net Operating Profit after Tax (NOPAT)	17	0.63	32	-2.75	-14	-31	-4.90	-10	26	43	47
Normalized NOPAT Margin	9.11%	0.29%	10.08%	-0.76%	-4.85%	-12.51%	-2.02%	-3.85%	8.08%	12.46%	11.19%
Pre Tax Income Margin	12.96%	0.25%	14.04%	-0.95%	-8.55%	-24.79%	-4.98%	-7.37%	9.53%	16.42%	15.83%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	283.30	0.00	519.25	0.00	-4.43	-2.81	-1.42	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	343.61	0.00	762.72	0.00	-3.15	-1.97	-0.99	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	215.55	0.00	460.33	0.00	-4.81	-3.07	-2.07	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	275.85	0.00	703.80	0.00	-3.52	-2.23	-1.64	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	136.79%	2,661.03%	105.46%	-25.26%	0.00%	-15.16%	0.00%	0.00%	16.34%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.49%	20.72%	16.75%	18.18%	7.32%	2.87%	7.00%	4.13%	13.07%	35.30%	27.11%
EBITDA Growth	236.23%	306.21%	33.51%	1,925.47%	110.09%	1.51%	-14.56%	-17.76%	-36.63%	122.46%	74.24%
EBIT Growth	212.15%	256.46%	37.14%	3,975.44%	114.80%	0.25%	-30.06%	-38.12%	-47.15%	98.04%	92.59%
NOPAT Growth	261.99%	309.71%	406.29%	4,504.13%	62.90%	-26.15%	-87.20%	-35.81%	-48.61%	111.21%	100.96%
Net Income Growth	111.04%	201.28%	13,017.15%	285.85%	1,368.75%	-5.14%	-86.09%	-24.17%	-45.43%	106.89%	104.21%
EPS Growth	109.09%	166.67%	1,900.00%	200.00%	1,100.00%	-16.67%	-86.11%	-16.67%	-50.00%	120.00%	100.00%
Operating Cash Flow Growth	358.74%	1,233.79%	282.38%	247.68%	180.57%	53.42%	83.11%	-11.36%	-33.90%	49.45%	32.87%
Free Cash Flow Firm Growth	142.75%	67.43%	-66.78%	-1,070.92%	-857.46%	-1,408.57%	252.72%	134.42%	131.73%	134.12%	26.10%
Invested Capital Growth	9.62%	27.77%	95.85%	104.77%	101.06%	85.12%	-2.00%	-9.48%	-3.69%	0.87%	0.81%
Revenue Q/Q Growth	13.37%	0.56%	6.27%	-2.45%	2.95%	-3.61%	10.53%	-5.06%	11.79%	15.33%	3.84%
EBITDA Q/Q Growth	1,583.12%	6.62%	29.27%	-16.93%	74.58%	-48.48%	8.81%	-15.96%	34.89%	77.20%	-11.86%
EBIT Q/Q Growth	3,297.34%	2.83%	39.55%	-17.18%	77.21%	-52.01%	-2.64%	-25.27%	51.36%	79.84%	-5.32%
NOPAT Q/Q Growth	4,690.93%	-4.57%	447.69%	-81.71%	69.80%	-56.73%	-5.09%	-7.94%	35.94%	77.82%	-9.69%
Net Income Q/Q Growth	124.08%	611.17%	526.63%	-82.68%	90.31%	-54.07%	-8.12%	-5.58%	36.95%	74.13%	-9.31%
EPS Q/Q Growth	116.67%	500.00%	500.00%	-83.33%	100.00%	-58.33%	0.00%	0.00%	20.00%	83.33%	-9.09%
Operating Cash Flow Q/Q Growth	292.07%	64.51%	-19.81%	-41.72%	264.90%	-10.04%	-4.29%	-71.79%	172.11%	103.41%	-14.91%
Free Cash Flow Firm Q/Q Growth	221.51%	-152.44%	191.11%	-1,967.41%	21.40%	-4.45%	121.30%	96.82%	-27.55%	12.33%	-9.54%
Invested Capital Q/Q Growth	-3.27%	2.69%	80.39%	14.28%	-5.02%	-5.45%	-4.51%	5.56%	1.05%	-0.98%	-5.81%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	83.28%	81.90%	84.06%	84.67%	82.97%	81.77%	81.80%	81.23%	81.05%	83.54%	83.86%
EBITDA Margin	14.23%	15.09%	18.36%	16.43%	27.86%	14.89%	14.66%	12.97%	15.66%	24.05%	20.42%
Operating Margin	13.34%	13.61%	17.84%	15.58%	26.89%	13.28%	11.90%	9.35%	12.55%	19.51%	17.85%
EBIT Margin	13.30%	13.60%	17.86%	15.46%	26.62%	13.25%	11.68%	9.19%	12.44%	19.40%	17.69%
Profit (Net Income) Margin	1.48%	10.44%	61.59%	10.93%	20.21%	9.63%	8.01%	7.96%	9.75%	14.73%	12.86%
Tax Burden Percent	13.08%	90.47%	384.34%	81.17%	75.92%	70.89%	66.12%	81.55%	73.94%	73.30%	69.69%
Interest Burden Percent	84.92%	84.88%	89.72%	87.10%	100.01%	102.50%	103.72%	106.24%	106.02%	103.56%	104.33%
Effective Tax Rate	-0.81%	6.27%	-268.61%	20.58%	24.10%	31.01%	33.88%	18.45%	26.06%	26.70%	30.31%
Return on Invested Capital (ROIC)	69.13%	71.79%	251.81%	43.78%	76.92%	35.75%	24.94%	22.21%	28.49%	49.11%	48.23%
ROIC Less NNEP Spread (ROIC-NNEP)	113.38%	78.44%	266.54%	49.71%	77.43%	34.95%	24.72%	21.71%	27.85%	48.60%	47.80%
Return on Net Nonoperating Assets (RNNOA)	-31.40%	-26.78%	-60.48%	-8.89%	-20.99%	-12.61%	-8.52%	-7.05%	-10.70%	-22.08%	-24.85%
Return on Equity (ROE)	37.73%	45.01%	191.32%	34.89%	55.93%	23.14%	16.42%	15.16%	17.79%	27.03%	23.38%
Cash Return on Invested Capital (CROIC)	16.28%	34.23%	32.52%	26.91%	37.73%	43.46%	41.23%	42.61%	29.85%	33.58%	42.58%
Operating Return on Assets (OROA)	22.74%	23.23%	27.97%	26.54%	44.58%	20.99%	16.20%	13.16%	17.37%	27.12%	24.42%
Return on Assets (ROA)	2.53%	17.84%	96.47%	18.76%	33.85%	15.25%	11.11%	11.40%	13.61%	20.59%	17.75%
Return on Common Equity (ROCE)	-6.24%	-4.91%	109.86%	20.88%	35.06%	15.35%	16.42%	15.16%	17.79%	27.03%	23.38%
Return on Equity Simple (ROE_SIMPLE)	99.66%	326.09%	0.00%	46.54%	52.90%	48.87%	0.00%	19.82%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	11	10	57	10	18	7.70	7.31	6.73	9.15	16	15
NOPAT Margin	13.45%	12.76%	65.77%	12.37%	20.41%	9.16%	7.87%	7.63%	9.28%	14.30%	12.44%
Net Nonoperating Expense Percent (NNEP)	-44.25%	-6.65%	-14.73%	-5.93%	-0.52%	0.80%	0.22%	0.51%	0.64%	0.51%	0.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	29.77%	-	-	-	3.43%	3.04%	3.89%	6.32%	5.35%
Cost of Revenue to Revenue	16.72%	18.10%	15.94%	15.33%	17.03%	18.23%	18.20%	18.77%	18.95%	16.46%	16.14%
SG&A Expenses to Revenue	63.94%	64.34%	62.59%	65.08%	63.53%	63.67%	65.70%	67.99%	65.06%	60.67%	61.88%
R&D to Revenue	4.52%	3.76%	2.80%	3.35%	3.45%	3.47%	3.84%	3.77%	3.35%	3.26%	4.03%
Operating Expenses to Revenue	69.94%	68.29%	66.22%	69.09%	56.08%	68.49%	69.90%	71.87%	68.51%	64.03%	66.02%
Earnings before Interest and Taxes (EBIT)	11	11	16	13	23	11	11	8.11	12	22	21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	12	16	14	24	13	14	11	15	27	24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	636.42	7.15	5.75	6.09	4.79	7.32	5.52	4.17	4.32	3.91
Price to Tangible Book Value (P/TBV)	0.00	0.00	8.65	7.24	7.49	5.77	8.72	6.50	4.87	4.96	4.50
Price to Revenue (P/Rev)	2.59	2.74	3.17	2.68	3.00	2.53	4.05	3.18	2.48	2.62	2.40
Price to Earnings (P/E)	0.00	0.00	17.53	6.36	6.83	5.78	33.33	27.87	28.05	25.30	20.64
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	5.71%	15.73%	14.65%	17.31%	3.00%	3.59%	3.57%	3.95%	4.85%
Enterprise Value to Invested Capital (EV/IC)	13.94	14.71	8.88	6.83	8.08	7.02	12.20	8.98	6.90	7.90	7.88
Enterprise Value to Revenue (EV/Rev)	2.84	2.93	3.07	2.59	2.86	2.34	3.81	2.93	2.20	2.31	2.04
Enterprise Value to EBITDA (EV/EBITDA)	44.81	24.52	24.38	15.98	14.56	11.92	20.66	16.68	16.33	14.16	10.93
Enterprise Value to EBIT (EV/EBIT)	57.03	27.57	26.63	17.16	15.50	12.72	22.80	19.36	18.93	17.06	13.49
Enterprise Value to NOPAT (EV/NOPAT)	57.27	28.16	12.09	9.59	10.29	8.83	30.81	26.11	25.95	23.03	18.24
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	83.23	36.89	23.56	19.18	13.88	20.08	15.75	13.80	13.40	11.55
Enterprise Value to Free Cash Flow (EV/FCFF)	89.58	48.22	36.17	34.08	28.61	20.97	29.30	20.01	22.68	23.62	18.59
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.61	0.52	0.34	0.12	0.13	0.12	0.10	0.09	0.09	0.08	0.07
Long-Term Debt to Equity	0.61	0.52	0.34	0.12	0.11	0.10	0.09	0.09	0.08	0.07	0.06
Financial Leverage	-0.28	-0.34	-0.23	-0.18	-0.27	-0.36	-0.34	-0.32	-0.38	-0.45	-0.52
Leverage Ratio	2.17	2.17	1.89	1.69	1.64	1.58	1.50	1.37	1.36	1.34	1.35
Compound Leverage Factor	1.85	1.84	1.70	1.47	1.64	1.61	1.55	1.46	1.44	1.39	1.41
Debt to Total Capital	37.96%	34.29%	25.60%	11.10%	11.32%	10.78%	9.49%	8.43%	7.85%	7.08%	6.55%
Short-Term Debt to Total Capital	0.00%	0.00%	0.52%	0.57%	1.69%	1.90%	1.13%	0.51%	0.53%	0.53%	0.55%
Long-Term Debt to Total Capital	37.96%	34.29%	25.08%	10.53%	9.63%	8.88%	8.36%	7.92%	7.32%	6.55%	6.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	71.89%	64.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-9.84%	0.93%	74.40%	88.90%	88.68%	89.22%	90.51%	91.57%	92.15%	92.92%	93.46%
Debt to EBITDA	2.62	1.32	1.21	0.36	0.32	0.33	0.31	0.30	0.38	0.28	0.23
Net Debt to EBITDA	-1.06	-0.87	-0.81	-0.54	-0.71	-1.00	-1.31	-1.42	-2.04	-1.93	-1.89
Long-Term Debt to EBITDA	2.62	1.32	1.19	0.34	0.27	0.27	0.28	0.28	0.35	0.26	0.21
Debt to NOPAT	3.34	1.52	0.60	0.22	0.23	0.24	0.47	0.47	0.60	0.46	0.38
Net Debt to NOPAT	-1.36	-1.00	-0.40	-0.32	-0.50	-0.74	-1.95	-2.22	-3.25	-3.14	-3.16
Long-Term Debt to NOPAT	3.34	1.52	0.59	0.20	0.19	0.20	0.41	0.44	0.56	0.43	0.35
Altman Z-Score	5.73	6.48	7.73	9.59	11.63	9.91	13.62	11.60	9.00	9.69	8.98
Noncontrolling Interest Sharing Ratio	116.55%	110.91%	42.58%	40.17%	37.32%	33.65%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.18	3.54	3.57	3.29	3.85	4.10	4.21	4.70	4.39	4.41	4.32
Quick Ratio	2.65	2.98	2.95	2.50	3.05	3.41	3.51	3.96	3.74	3.82	3.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5.66	-2.97	2.70	-55	-43	-45	9.54	19	14	15	14
Operating Cash Flow to CapEx	2,600.33%	2,036.78%	2,402.11%	97.30%	4,631.42%	11,476.02%	0.00%	1,405.57%	8,055.31%	15,275.52%	8,756.49%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-32.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	3.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.71	1.71	1.57	1.72	1.67	1.58	1.39	1.43	1.40	1.40	1.38
Accounts Receivable Turnover	6.81	6.88	6.63	6.58	6.69	6.65	6.36	5.91	5.96	5.95	6.37
Inventory Turnover	3.48	3.34	3.19	2.82	2.70	2.63	2.68	2.62	2.70	2.79	2.97
Fixed Asset Turnover	0.00	41.19	43.36	44.89	48.35	50.62	54.01	53.74	59.58	68.70	78.56
Accounts Payable Turnover	6.48	6.13	6.24	6.30	7.17	7.08	7.30	6.86	8.38	7.73	6.66
Days Sales Outstanding (DSO)	53.59	53.05	55.04	55.49	54.55	54.85	57.38	61.79	61.22	61.33	57.34
Days Inventory Outstanding (DIO)	104.85	109.33	114.26	129.30	135.31	138.68	136.19	139.14	135.10	130.70	122.85
Days Payable Outstanding (DPO)	56.34	59.52	58.46	57.92	50.91	51.52	50.00	53.24	43.55	47.23	54.83
Cash Conversion Cycle (CCC)	102.10	102.86	110.83	126.87	138.95	142.01	143.57	147.70	152.76	144.80	125.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	60	62	111	127	121	114	109	115	116	115	108
Invested Capital Turnover	5.14	5.63	3.83	3.54	3.77	3.90	3.17	2.91	3.07	3.43	3.88
Increase / (Decrease) in Invested Capital	5.27	13	54	65	61	52	-2.23	-12	-4.45	0.99	0.87
Enterprise Value (EV)	837	907	988	867	975	801	1,329	1,032	802	909	854
Market Capitalization	764	846	1,021	896	1,023	868	1,414	1,120	902	1,033	1,003
Book Value per Share	($0.11)	$0.01	$1.23	$1.06	$1.14	$1.23	$1.31	$1.38	$1.47	$1.61	$1.73
Tangible Book Value per Share	($0.33)	($0.20)	$1.01	$0.85	$0.93	$1.02	$1.10	$1.17	$1.25	$1.41	$1.51
Total Capital	129	143	192	175	189	203	213	221	235	257	275
Total Debt	49	49	49	19	21	22	20	19	18	18	18
Total Long-Term Debt	49	49	48	18	18	18	18	18	17	17	16
Net Debt	-20	-32	-33	-29	-48	-67	-84	-88	-100	-124	-148
Capital Expenditures (CapEx)	0.30	0.63	0.43	6.14	0.47	0.17	-5.10	0.38	0.18	0.19	0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	28	30	37	49	48	45	44	52	53	56	49
Debt-free Net Working Capital (DFNWC)	97	111	119	98	117	134	149	159	172	198	215
Net Working Capital (NWC)	97	111	118	97	114	130	146	157	171	196	213
Net Nonoperating Expense (NNE)	9.73	1.89	3.63	1.22	0.17	-0.39	-0.13	-0.29	-0.47	-0.48	-0.50
Net Nonoperating Obligations (NNO)	-20	-32	-32	-29	-47	-67	-84	-88	-100	-124	-148
Total Depreciation and Amortization (D&A)	0.76	1.22	0.43	0.82	1.08	1.37	2.77	3.34	3.17	5.29	3.22
Debt-free, Cash-free Net Working Capital to Revenue	9.53%	9.61%	11.59%	14.69%	14.15%	13.20%	12.70%	14.81%	14.56%	14.16%	11.61%
Debt-free Net Working Capital to Revenue	32.80%	35.88%	37.10%	29.19%	34.42%	39.11%	42.63%	45.01%	47.24%	50.27%	51.29%
Net Working Capital to Revenue	32.80%	35.88%	36.78%	28.89%	33.49%	37.98%	41.93%	44.69%	46.89%	49.92%	50.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.06	$0.40	$0.06	$0.12	$0.05	$0.06	$0.05	$0.07	$0.11	$0.10
Adjusted Weighted Average Basic Shares Outstanding	115.87M	116.30M	116.50M	146.40M	147.33M	146.96M	146.98M	147.27M	147.76M	148.04M	147.79M
Adjusted Diluted Earnings per Share	$0.00	$0.06	$0.36	$0.06	$0.12	$0.05	$0.05	$0.05	$0.06	$0.11	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	115.87M	119.33M	145.96M	150.03M	148.90M	148.37M	149.05M	149.68M	149.32M	149.71M	149.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	116.11M	116.38M	146.96M	147.60M	146.81M	146.95M	147.37M	147.70M	147.96M	148.10M	148.57M
Normalized Net Operating Profit after Tax (NOPAT)	7.59	10	11	11	18	7.91	7.37	6.73	9.15	16	15
Normalized NOPAT Margin	9.34%	12.76%	12.49%	12.42%	20.41%	9.41%	7.93%	7.63%	9.28%	14.30%	12.44%
Pre Tax Income Margin	11.29%	11.54%	16.02%	13.47%	26.62%	13.58%	12.11%	9.76%	13.19%	20.09%	18.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	7.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	6.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	4.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	2.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	16.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

MiMedx Group (MDXG) has shown improving profitability and cash flow across 2025, with a clear path toward higher quarterly revenue and stronger margins. Below are the key trends distilled from the last four years of quarterly results, focusing on the most recent four quarters of 2025 and notable longer-term patterns.

Q4 2025 revenue reached $118.095 million, up from $113.725 million in Q3 2025 and showing continued year-over-year growth through 2025.
Total gross profit in Q4 2025 was $99.040 million, yielding a gross margin of roughly 83.9% (about 84%), indicating strong product profitability despite rising operating costs.
Net cash from continuing operating activities rose sharply, with CFO at $24.956 million in Q4 2025 and peaking at $29.329 million in Q3 2025, reflecting robust cash generation.
Net income attributable to common shareholders climbed to $15.19 million in Q4 2025, marking a significant profitability improvement relative to earlier periods.
Long-term debt declined to about $16.84 million by Q4 2025 (from $17.53 million earlier in 2025), signaling improving leverage and balance sheet strength.
Selling, general & administrative expenses remained elevated relative to revenue (SG&A around $73.07 million in Q4 2025, with RD expense about $4.76 million), contributing to a sizable operating expense base.
Earnings per share were generally around $0.10 (Q4 2025 basic and diluted EPS both $0.10), with modest quarterly variation but a stable bottom-line signal for the period.
Total assets expanded toward roughly $319 million by Q3 2025, reflecting ongoing investments in intangibles and other assets as the company grows.
The company posted net losses in several earlier periods (notably Q4 2023 and Q4 2022), underscoring a history of profitability volatility before the 2024–2025 turnaround.
Investing cash outflows have remained meaningful at times (e.g., Q3 2025 investing outflow around $5.26 million and Q4 2025 around $0.33 million), which can pressure near-term liquidity if cash generation slows.

05/05/26 06:07 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About MiMedx Group's Financials

When does MiMedx Group's financial year end?

According to the most recent income statement we have on file, MiMedx Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has MiMedx Group's net income changed over the last 10 years?

MiMedx Group's net income appears to be on an upward trend, with a most recent value of $48.58 million in 2025, rising from $29.45 million in 2015. The previous period was $42.42 million in 2024. Check out MiMedx Group's forecast to explore projected trends and price targets.

What is MiMedx Group's operating income?

MiMedx Group's total operating income in 2025 was $63.89 million, based on the following breakdown:

Total Gross Profit: $345.62 million
Total Operating Expenses: $281.73 million

How has MiMedx Group's revenue changed over the last 10 years?

Over the last 10 years, MiMedx Group's total revenue changed from $187.30 million in 2015 to $418.63 million in 2025, a change of 123.5%.

How much debt does MiMedx Group have?

MiMedx Group's total liabilities were at $86.11 million at the end of 2025, a 21.6% increase from 2024, and a 208.3% increase since 2015.

How much cash does MiMedx Group have?

In the past 10 years, MiMedx Group's cash and equivalents has ranged from $27.48 million in 2017 to $166.12 million in 2025, and is currently $166.12 million as of their latest financial filing in 2025.

How has MiMedx Group's book value per share changed over the last 10 years?

Over the last 10 years, MiMedx Group's book value per share changed from 0.99 in 2015 to 1.73 in 2025, a change of 74.8%.

Related Companies

Financial statements for NASDAQ:MDXG last updated on 2/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About MiMedx Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Financials

Annual Income Statements for MiMedx Group

Quarterly Income Statements for MiMedx Group

Annual Cash Flow Statements for MiMedx Group

Quarterly Cash Flow Statements for MiMedx Group

Annual Balance Sheets for MiMedx Group

Quarterly Balance Sheets for MiMedx Group

Annual Metrics And Ratios for MiMedx Group

Quarterly Metrics And Ratios for MiMedx Group

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About MiMedx Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools